Cash and cash equivalents: As of September 30, 2025, the Company had cash and cash equivalents of approximately $6.4 million, compared to approximately $21.3 million as of December 31, 2024.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW:
- Traws Pharma’s New COVID-19 Drug Trial: A Potential Game-Changer?
- Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics
- Traws Pharma Approves Executive Stock Options Grant
- Traws Pharma Begins Phase 2 COVID-19 Treatment Study
- Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies